Table 3.
Details of patients and lesions with tumor progression.
| ID | Lesion size (mm) | Dose (Gy) | Progression type | PFS time (months) | Further treatment | Follow-up time (month) | Current status |
|---|---|---|---|---|---|---|---|
| 1 | 15 | 36 | LTP | 1.6 | Ablation | 25.9 | DOD |
| 2 | 38 | 39 | IDR | 1.6 | Best Care | 6.0 | Lost |
| 3 | 68 | 39 | IDR | 1.7 | TACE | 6.3 | Lost |
| 4 | 48 | 42 | IDR | 5.9 | TACE | 7.2 | Lost |
| 5 | 29 | 48 | IDR | 11.0 | Ablation | 35.8 | AWD |
| 6 | 25 | 42 | IDR | 19.1 | Ablation | 25.2 | AWD |
| 7 | 20 | 54 | ER | 3.6 | Best Care | 3.6 | DOD |
| 8 | 47 | 48 | LTP + IDR | 2.1 | Best Care | 3.4 | Lost |
| 9 | 69 | 45 | LTP + IDR | 6.3 | TACE | 12.2 | Lost |
| 10† | 24 | 39 | LTP + IDR | 14.9 + 4.0† | TACE | 36.6 | AWD |
| 11 | 28 | 45 | LTP + IDR | 26.2 | LR | 36.0 | AWD |
| 12 | 19 | 42 | LTP + ER | 1.7 | CIK | 1.7 | Lost |
| 13 | 41 | 45 | IDR + ER | 4.8 | Best Care | 13.9 | Lost |
Abbreviations: LTP, local tumor progression; IDR, intrahepatic distance recurrence; ER, extrahepatic recurrence; TACE, transarterial chemoembolization; LR, liver resection; DOD, dead as a result of disease; AWD, alive with disease; Lost, lost to follow-up. † This patient was confirmed to have IDR 4.0 months after SBRT and received TACE as a salvage therapy. LTP was confirmed 14.9 months after SBRT, and TACE was performed on this patient again.